Earnings summaries and quarterly performance for Indaptus Therapeutics.
Executive leadership at Indaptus Therapeutics.
Board of directors at Indaptus Therapeutics.
Research analysts covering Indaptus Therapeutics.
Recent press releases and 8-K filings for INDP.
Indaptus Enters $6 Million Securities Agreement, Appoints New Co-CEO and Chairman
INDP
Convertible Preferred Issuance
CEO Change
Board Change
- Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, which closed on December 23, 2025.
- Under the agreement, Indaptus will issue 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of non-voting convertible Series AAA preferred stock to Mr. Lazar.
- David E. Lazar has been appointed Co-Chief Executive Officer and Chairman of the Board of Indaptus, while Jeffrey Meckler continues as Co-CEO.
- The company's Board was reconstituted, with Avraham Ben-Tzvi joining and Hila Kara and Dr. Robert Martell stepping down.
- Conversion of the preferred shares into common stock is contingent upon stockholder approval at a meeting anticipated in the first quarter of 2026.
Dec 29, 2025, 12:00 PM
Indaptus Therapeutics Secures $6 Million Investment and Appoints New Leadership
INDP
Convertible Preferred Issuance
CEO Change
Board Change
- Indaptus Therapeutics, Inc. entered into a Securities Purchase Agreement with David Lazar on December 22, 2025, for an investment of $6.0 million in convertible preferred stock, with the offering closing on December 23, 2025.
- The preferred stock is convertible into a combined total of 111,000,000 shares of Common Stock upon stockholder approval.
- David Lazar was appointed Chairman of the Board of Directors and Co-Chief Executive Officer.
- Avraham Ben-Tzvi was appointed to the Board of Directors, while Robert E. Martell and Hila Karah resigned.
- Employment agreements for Jeffrey Meckler (now Co-CEO) and Walt Linscott, Esq. (COO) were modified, including new annual salaries of $595,000 and $491,000, respectively, and equity settlement payments.
Dec 23, 2025, 10:22 PM
Indaptus Therapeutics Reports Q3 2025 Financial Results and Pauses Clinical Trial Enrollment
INDP
Earnings
Guidance Update
Debt Issuance
- Indaptus Therapeutics reported a net loss per share of $2.98 for the third quarter ended September 30, 2025, compared to $9.04 for the same period in 2024. Research and development expenses for Q3 2025 were $1.52 million, while general and administrative expenses were $1.1 million.
- The company paused enrollment in its Decoy20 and tislelizumab combination study after completing the Safety Lead-In cohort, where three out of six participants achieved stable disease. The Safety Review Committee determined the combination appears tolerable, but further efficacy evaluations are pending.
- As of September 30, 2025, Indaptus had $5.8 million in cash and cash equivalents, which is expected to support ongoing operating activities into the first quarter of 2026. The company raised approximately $2.3 million through its at-the-market facility in September 2025 and completed the conversion of $5.7 million in promissory notes in July 2025.
Nov 12, 2025, 1:30 PM
Indaptus Therapeutics Reports Q3 2025 Financial Results and Clinical Trial Update
INDP
Earnings
Guidance Update
New Projects/Investments
- Indaptus Therapeutics reported a net loss per share of $2.98 for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held approximately $5.8 million in cash and cash equivalents, which is expected to support ongoing operating activities into the first quarter of 2026.
- In September 2025, Indaptus raised approximately $2.3 million in gross proceeds through its at-the-market facility, further strengthening its balance sheet.
- The Safety Lead-In cohort for the Decoy20 and tislelizumab combination trial was completed, with three out of six evaluable participants achieving stable disease at the first assessment, though enrollment has been paused pending additional efficacy evaluations.
Nov 12, 2025, 1:30 PM
Indapta Therapeutics Presents Positive Clinical Data for IDP-023 in Multiple Myeloma
INDP
- Indapta Therapeutics presented positive clinical data for its IDP-023 allogeneic g-NK cell therapy in patients with relapsed/refractory multiple myeloma at the Society for Immunotherapy of Cancer (SITC) annual meeting.
- The data demonstrated marked tumor reduction in patients treated with IDP-023 alone and in combination with isatuximab.
- Specifically, 4 of 5 response evaluable patients treated with IDP-023 at the second dose level of 10 billion cells/dose in combination with isatuximab showed confirmed responses, including a stringent complete response in a heavily pre-treated patient.
- The treatment was generally well-tolerated, with no dose-limiting toxicities observed.
Nov 7, 2025, 2:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more